Skip to main content
This block is broken or missing. You may be missing content or you might need to enable the original module.
Home

Main sub menu

  • Investors
  • Careers
    • Working at Recipharm
    • The Recipharm story
    • Meet our employees
    • Current vacancies
  • Contact
    • Contact us
    • Development services contacts
    • Manufacturing services contacts
    • Locations
      • France
        • Fontaine
        • Kaysersberg
        • Monts
        • Pessac
      • Germany
        • Monheim
        • Wasserburg
        • Zwickau
      • India
        • Bengaluru
        • Karnal / Paonta Sahib
      • Israel
        • Ness Ziona
      • Italy
        • Brescia
        • Lainate
        • Masate
        • Paderno Dugnano
        • Pianezza
      • Portugal
        • Odivelas
        • Queluz
      • Spain
        • Parets
        • Leganés
      • Sweden
        • Höganäs
        • Stockholm city (HQ)
        • Karlskoga
        • Solna
        • Strängnäs
        • Uppsala
        • Uppsala Development
      • UK
        • Cramlington
        • Holmes Chapel
        • Queenborough
        • King’s Lynn
      • USA
        • Research Triangle Park

Main navigation

  • Development
    • Drug substance
    • Drug product
    • Analytical chemistry
    • Clinical trial material (CTM)
  • Manufacturing
    • Solids
    • Semi-solids
    • Liquids
    • Inhalation
    • Injectables
    • Ophthalmics
  • Solutions
    • Recipharm Analytical Solutions™
    • Recipharm Inhalation Solutions™
    • Recipharm Pathway to Clinic®
    • Serialisation
  • Bespak
  • Learn
  • Press & events
    • Press
    • Events
    • Reports
    • Insights
  • Our story
    • Recipharm in brief
    • Business model
    • Sustainability
    • Company history

Press & events

What's happening?

Stay updated on our latest news and events.

Press and Event

  • Press
  • Events
  • Reports
  • Insights
Displaying 1 - 10 of 31

Subscribe

Press

Recipharm partners with Aptahem for formulation of Apta-1 drug candidate

2019.12.17 Read more

Press

Recipharm invests in its US inhalation development service

2019.12.09 Read more

Press

Recipharm publishes Offer Document regarding offer to acquire Consort Medical

2019.12.06 Read more

Press

Recipharm announces commercial manufacturing to support Talicia[®] Q1/2020 Launch following U.S. FDA approval

2019.11.27 Read more

Press

Larger institutional shareholders support Recipharm’s cash offer for Consort Medical and subsequent rights issue

2019.11.26 Read more

Press

Recipharm Offers to Acquire Consort Medical to Become a Leading Inhalation Company and Top Five Global CDMO Player

2019.11.18 Read more

Press

Recipharm to communicate new financial targets on Capital Markets Day

2019.11.18 Read more

Press

Recipharm joins the AMR Industry Alliance

2019.11.14 Read more

Press

Recipharm AB publishes its interim report January - September 2019

2019.11.07 Read more

Press

Recipharm expands Indian injectable dosage form capabilities through new partnership

2019.11.06 Read more

Pagination

  • Current page 1
  • Page 2
  • Page 3
  • Page 4
  • Next page Next ›
  • Last page Last »

Footer menu

  • Privacy policy
  • Cookies
  • Website terms
© 2021 Recipharm AB (publ). All rights reserved Stormfors Digitalbyrå